Evolus (EOLS) to Release Quarterly Earnings on Wednesday

Evolus (NASDAQ:EOLS - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $73.06 million for the quarter.

Evolus Trading Up 0.1 %

NASDAQ:EOLS traded up $0.01 during mid-day trading on Monday, hitting $12.09. The company had a trading volume of 89,303 shares, compared to its average volume of 662,669. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus has a fifty-two week low of $8.67 and a fifty-two week high of $17.82. The firm has a market cap of $779.52 million, a P/E ratio of -13.30 and a beta of 1.11. The business's fifty day moving average is $11.98 and its two-hundred day moving average is $12.71.

Insider Buying and Selling

In other Evolus news, insider Rui Avelar sold 27,904 shares of Evolus stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $370,007.04. Following the sale, the insider now owns 362,467 shares of the company's stock, valued at $4,806,312.42. This trade represents a 7.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider David Moatazedi sold 6,251 shares of the company's stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the transaction, the insider now directly owns 508,619 shares of the company's stock, valued at $6,306,875.60. This represents a 1.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 60,575 shares of company stock valued at $794,369. 6.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

EOLS has been the topic of several recent analyst reports. Barclays lifted their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Needham & Company LLC reissued a "buy" rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, April 9th. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Finally, BTIG Research started coverage on Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Evolus presently has a consensus rating of "Buy" and an average target price of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.